HATCHER GROUP (08365) plans to discount about 11.29% for the rights issue, with a maximum net proceeds of approximately HK$29.6 million.
Yichen Group (08365) announced that on November 4, 2025, the company entered into a placement agreement with the placement agents, whereby...
HATCHER GROUP (08365) announced on November 4, 2025, that the company has entered into a placing agreement with the placing agent. The company intends to place up to 18 million shares with no fewer than six placees through the placing agent at a price of HK$1.65 per share. This represents a discount of approximately 11.29% to the closing market price of HK$1.86 per share on the date of the placing agreement announced on the Stock Exchange.
Assuming all 18 million placing shares are fully placed, the net proceeds are expected to be approximately HK$29.6 million. Around 80% of the proceeds will be used for the general operating expenses of the group, while approximately 20% will be used for marketing and investor relations expenses.
Related Articles

Infotmic Co., Ltd. shareholder Orient intends to reduce its shareholding by no more than 3%.

US Stock Market Move | Palantir (PLTR.US) fell more than 6.7% in response to its impressive Q3 financial report, but the market is concerned that its valuation is too high.

US Stock Market Move | Royal Philips N.V. Sponsored ADR (PHG.US) rises 3% in Q3, adjusted EBITA exceeds expectations.
Infotmic Co., Ltd. shareholder Orient intends to reduce its shareholding by no more than 3%.

US Stock Market Move | Palantir (PLTR.US) fell more than 6.7% in response to its impressive Q3 financial report, but the market is concerned that its valuation is too high.

US Stock Market Move | Royal Philips N.V. Sponsored ADR (PHG.US) rises 3% in Q3, adjusted EBITA exceeds expectations.

RECOMMEND

World’s largest oil company Aramco posts higher Q3 net profit after lifting output
04/11/2025

HSBC, General Atlantic CEOs flag AI capex-revenue mismatch, ‘irrational exuberance’
04/11/2025

Pfizer Files Second Lawsuit Against Novo Nordisk and Metsera Amid Intensifying Bidding Battle Over Obesity Biotech
04/11/2025


